Update on the management of hypertension: do recent clinical trial results indicate a change in national recommendations for therapy? [0.03%]
高血压治疗现状：最近的临床试验结果是否预示着国家治疗指南的变化？
Marvin Moser
Marvin Moser
Numerous hypertension treatment trials have been reported during the past several years. In comparative studies it has been shown that the use of diuretics or diuretics/beta blockers has resulted in a reduction in morbidity/mortality equiva...
Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists [0.03%]
肾素血管紧张素系统阻断的临床影响：血管紧张素转换酶抑制剂与血管紧张素受体拮抗剂的差异
Joseph L Izzo Jr,Marvin Moser
Joseph L Izzo Jr
Clinical trials have proved that blockade of the renin-angiotensin-aldosterone system (RAAS) offers primary and secondary protection of the cardiovascular system, brain, and kidneys. Drugs that interrupt the RAAS do so by several diverse me...
Thomas D Giles
Thomas D Giles
Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate? [0.03%]
依普利酮：一个新的醛固酮受体拮抗剂——美国FDA的限制措施是否合适？
D A Sica
D A Sica
Eplerenone is a new aldosterone receptor antagonist that will be used in the treatment of hypertension. Like spironolactone, it is a compound that can be associated with the development of hyperkalemia. Therefore, the same prescription cons...
Thomas G Pickering
Thomas G Pickering
Raymond R Townsend
Raymond R Townsend
Sexual dysfunction in patients with hypertension: implications for therapy [0.03%]
高血压患者的性功能障碍：治疗的临床意义
Carlos M Ferrario,Pavel Levy
Carlos M Ferrario
Sexual dysfunction associated with hypertension or antihypertensive therapies may impact the ability of patients to stay on therapy and lead to deterioration in patients' quality of life. Therefore, it is important for practitioners to beco...